NSE: LUPIN | BSE: 500257

Mid-range Performer

Download real time

1919.80 -43.70 (-2.23%)

1.1M NSE+BSE Volume

NSE 26 Sep, 2025 3:31 PM (IST)

87,688.4

Market Cap

High in industry

0.9

Beta 1Year

Low volatility

US FDA Approval

Lupin gets US FDA tentative nod for its ANDA for HIV treatment tablets with a market size of $16 bn See details

Lupin Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LUPIN, BSE:500257 Lupin Ltd.

Lupin Ltd.

07 Aug 2023

1919.80

-2.23%

Result Update:Lupin

Buy: Lupin Ltd.

Target

Axis Direct

Company Outlook and Guidance: We have confidence in Lupins business and its long-term prospects, which is supported by these factors: 1) New launches in the US market like Darunavir, Cynocobalamin, Diazepem Gel, Vereniciline, Bromfenac, etc.

Lupin Ltd.'s price crossed below 50Day SMA today

Lupin Ltd.

06 Aug 2023

1919.80

-2.23%

Margin improvement in line with estimates; Spiriva launch awaited

Sell: Lupin Ltd.

Target

ICICI Securities Limited

Lupin’s Q1FY24 result was boosted by better performance in India and the US, and milestone income it received from Abbvie (USD 25mn). Sequential growth of 3% in the US was driven by Darunavir, while the acute portfolio is unlikely to have seen traction from the drug shortages in the US.

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

05 Aug 2023

1919.80

-2.23%

Niche approval to aid further improvement in profitability

Sell: Lupin Ltd.

Target

Motilal Oswal

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

05 Aug 2023

1919.80

-2.23%

Lupin (SELL): Improvements visible; runup behind downgrade

Sell: Lupin Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Q1 a beat with revenue/EBITDA running 8%/25% ahead of consensus; gross margin improves to 65.9% (64.4 ex-licensing income)

Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.

Lupin Ltd.

08 Jul 2023

1919.80

-2.23%

Pick of the Week:10 JULY 2023

Buy: Lupin Ltd.

Target

Axis Direct

Recommendation: We recommend a BUY rating for a target price of Rs 990/share, implying an upside of 10% from the CMP.

Lupin Ltd. is trading below all available SMAs

Lupin Ltd.

23 Jun 2023

1919.80

-2.23%

Lupin

Sell: Lupin Ltd.

Target

Sharekhan

Lupin Ltd.'s price crossed below 50Day SMA today

Lupin Ltd.

22 Jun 2023

1919.80

-2.23%

gSpiriva to rejuvenate margins

Sell: Lupin Ltd.

Target

ICICI Securities Limited

Lupin is the first company globally to receive the final approval of the USFDA for US$1.264bn inhalation drug gSpiriva (Tiotropium Bromide). We factor in US$100mn revenue from this drug in FY24E.

Lupin Ltd.'s price crossed below 50Day SMA today

Lupin Ltd.

21 Jun 2023

1919.80

-2.23%

Company Update:Lupin

Buy: Lupin Ltd.

Target

Axis Direct

We believe both these products could increase the gross margins by 100 bps in next two years. We have increased our target price to Rs 950 (from Rs 825) with Buy recommendations.